Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.22.02819 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Bhavika K Patel und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic in Arizona, Phoenix, AZ. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammography, Contrast Media, Early Detection of Cancer. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) have shown similar diagnostic performance in detection of breast cancer. Limited CEM data are available for high-risk breast cancer screening. The purpose of the study was to prospectively investigate the efficacy of supplemental screening CEM in elevated risk patients. MATERIALS AND METHODS A prospective, single-institution, institutional review board–approved observational study was conducted in asymptomatic elevated risk women age 35 years or older who had a negative conventional two-dimensional digital breast tomosynthesis screening mammography (MG) and no additional supplemental screening within the prior 12 months. RESULTS Four hundred sixty women were enrolled from February 2019 to April 2021. The median age was 56.8 (range, 35.0-79.2) years; 408 of 460 (88.7%) were mammographically dense. Biopsy revealed benign changes in 22 women (22/37, 59%), high-risk lesions in four women (4/37, 11%), and breast cancer in 11 women (11/37, 30%). Fourteen cancers (10 invasive, tumor size range 4-15 mm, median 9 mm) were diagnosed in 11 women. The overall supplemental cancer detection rate was 23.9 per 1,000 patients, 95% CI (12.0 to 42.4). All cancers were grade 1 or 2, ER+ ERBB2–, and node negative. CEM imaging screening offered high specificity (0.875 [95% CI, 0.844 to 0.906]), high NPV (0.998 [95% CI, 0.993 to 1.000), moderate PPV1 (0.164 [95% CI, 0.076 to 0.253), moderate PPV3 (0.275 [95% CI, 0.137 to 0.413]), and high sensitivity (0.917 [95% CI, 0.760 to 1.000]). At least 1 year of imaging follow-up was available on all patients, and one interval cancer was detected on breast MRI 4 months after negative screening CEM. CONCLUSION A pilot trial demonstrates a supplemental cancer detection rate of 23.9 per 1,000 in women at an elevated risk for breast cancer. Larger, multi-institutional, multiyear CEM trials in patients at elevated risk are needed for validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic in Arizona, Phoenix, AZ.
- Department of Medical Oncology, Mayo Clinic in Arizona, Phoenix, AZ.
- Department of Quantitative Health Sciences, Mayo Clinic in Arizona, Phoenix, AZ.
- Division of Women's Health Internal Medicine, Mayo Clinic in Arizona, Phoenix, AZ.
- Department of Surgical Oncology, Mayo Clinic in Arizona, Phoenix, AZ.
ORCID-Profile: Bhavika K Patel, Molly B Carnahan, Donald Northfelt, Gina L Mazza, Victor J Pizzitola, Richard E Sharpe, Laura K Harper, Juliana Kling, Brenda Ernst, Jessica Fraker, Felipe Batalini
Zitieren
APA
Patel, B. K., Carnahan, M. B., Northfelt, D., Anderson, K., Mazza, G. L., Pizzitola, V. J., Giurescu, M. E., Lorans, R., Eversman, W. G., Sharpe, R. E., Harper, L. K., Apsey, H., Cronin, P., Kling, J., Ernst, B., Palmieri, J., Fraker, J., Mina, L., Batalini, F., & Pockaj, B. (2024). Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02819
Vancouver
Patel BK, Carnahan MB, Northfelt D, Anderson K, Mazza GL, Pizzitola VJ, et al. Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. Journal of Clinical Oncology. 2024. doi:10.1200/jco.22.02819
BibTeX
@article{Patel2024,
author = {Patel, Bhavika K and Carnahan, Molly B and Northfelt, Donald and Anderson, Karen and Mazza, Gina L and Pizzitola, Victor J and Giurescu, Marina E and Lorans, Roxanne and Eversman, William G and Sharpe, Richard E and Harper, Laura K and Apsey, Heidi and Cronin, Patricia and Kling, Juliana and Ernst, Brenda and Palmieri, Jennifer and Fraker, Jessica and Mina, Lida and Batalini, Felipe and Pockaj, Barbara},
title = {Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.22.02819}
}
EUVIMED